Squamous Cell Carcinoma (SCC)

Squamous cell carcinoma (SCC Tumor Marker) antigen is a 48kDa glycoprotein initially isolated from a squamous cancer of the uterine cervix.

Immunohistochemically, SCC is a cytoplasmic protein of normal and cancerous squamous cells.

Studies have indicated that SCC antigen is a good marker for diagnosis and monitoring the effectiveness of treatment of SCCs.

The clinical significance of SCC is as follows:

1. It has a high diagnostic value for cervical cancer

2. Assist in the diagnosis of lung squamous cell carcinoma

3. Prediction of esophageal squamous cell carcinoma

4. Diagnosis and monitoring of other squamous cell cancers (head and neck cancer, vulva cancer, bladder cancer, anal cancer, skin cancer, etc.)

Squamous Cell Carcinoma (SCC Tumor Marker) Products

Mouse anti-human SCC mAb

For immunodiagnostic: ELISA, LFA, CLIA

Humanized anti-human SCC mAb
Prokaryotic expression antigen (full length)

Prokaryotic expression antigen (full length)For immunodiagnostic: ELISA, LFA, CLIA

SCC Tumor Marker

Squamous cell carcinoma, also known as epidermal carcinoma, is a malignant tumor that occurs in the epidermis or adnexal cells, and the cancer cells have different degrees of keratinization. It is more common in areas covered by squamous epithelium, such as the skin, mouth, lips, esophagus, cervix, vagina, etc. In addition, some parts such as the bronchus, bladder, renal pelvis, etc., although not covered by squamous epithelium, can form squamous cell carcinoma through squamous metaplasia.


Serum SCCA assay has high specificity for diagnosing various squamous cell carcinomas. It is an effective and sensitive marker for squamous cell carcinomas of the vulva, vagina, and cervix. For primary cancer of the vulva and vagina, the sensitivity is 40%-50%; for primary cervical squamous cell carcinoma, the diagnostic sensitivity can reach 50%-70%; the sensitivity for the diagnosis of recurrent cancer can get 65%-85%. The serum SCCA in patients with cervical cancer is positively correlated with the clinical stage. The rise and fall of the SCCA level are consistent with the progression or improvement of the disease. Dynamic monitoring of serum SCCA levels can indicate cervical cancer disease monitoring. Serum SCCA levels in patients with cervical cancer rise again after treatment, or serum SCCA is negative before treatment. Elevated SCCA levels are earlier than clinical signs of recurrence or imaging suggestive of tumor recurrence.

It is worth noting that SCCA can also be found in normal body fluids such as sweat, saliva, and other body fluids. If such body fluids contaminate the specimen, even sneezing may pollute the specimen and cause false positives. Therefore, the sample with elevated SCCA should be repeated for determination.